NCT00390468View on ClinicalTrials.gov

Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Metastatic CancerPainProstate Cancer
Interventions
DRUG

Tandutinib

500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.

Trial Locations (1)

77030-4009

M. D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00390468 - Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases | Biotech Hunter | Biotech Hunter